Key facts
- This page summarizes Kristin Yarema's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2022, 18:02.
Kristin Yarema - 01 Mar 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ATRA
- Reported as of
- 01 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 18:02:35 UTC
- Prior SEC filing
- 15 Jun 2021
- Next SEC filing
- 12 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Tucker, Attorney-in-Fact for Kristin Yarema
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kristin Yarema filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 15 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +45,533
- Change %
- +36%
- Price
- $0.000000
- Shares after
- 171,415
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATRA
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +85,592
- Change %
- Price
- $0.000000
- Shares after
- 85,592
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,592
- Exercise price
- $10.21
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
Footnote F2
1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.